Federal investigators intervened after an alleged eighteen-month wound-care operation generated more than $118 million in Medicare billings, produced over $61 million in program payments, and left prosecutors tracing disputed reimbursements through medical files, business accounts, referral relationships, and substantial asset seizures.
WASHINGTON, DC — Medicare paid more than $61 million to Sarasota nurse practitioner Leigh Tesar and Tesar Primecare after receiving over $118 million in wound-care claims that prosecutors now describe as false, medically unnecessary, ineligible, unperformed, or corrupted by illegal kickbacks.
The extraordinary payment figure sits at the center of a ten-count federal case charging Tesar, registered nurse Walter Presha Junior, and registered nurse Koby Evans in an alleged operation that prosecutors say ran from approximately May 2024 through November 2025.
The twenty-one-page federal indictment alleges that high-priced skin allografts became the financial engine for a referral network in which disputed treatments generated Medicare reimbursements, purported sales representatives received money connected to patients, and clinical records allegedly concealed noncompliant care.
No court has found Tesar, Presha, or Evans guilty, and every allegation described in the indictment remains subject to evidentiary challenges, defense arguments, constitutional protections, and the government’s obligation to prove each charged offense beyond a reasonable doubt.
Why the $61 Million Payment Matters
The difference between more than $118 million billed and more than $61 million paid illustrates how Medicare claims move through an adjudication system that may reduce, adjust, deny, or approve charges rather than automatically transferring every dollar requested by a provider.
Prosecutors nevertheless treat the paid amount as an alleged program loss and the submitted amount as evidence of the operation’s intended scale, because unsuccessful, reduced, or partially paid claims can still help demonstrate the scope of an alleged scheme.
For taxpayers, the payment total represents money that actually left the federal insurance program, while the larger billing total shows the volume of reimbursement sought through treatment records and claim submissions that investigators contend did not satisfy Medicare’s conditions.
For the defendants, those two figures require careful separation, because a dramatic aggregate does not by itself establish that every treatment lacked medical value, every record contained a knowing falsehood, or every payment resulted from intentional criminal conduct.
The government must connect particular claims to particular alleged misrepresentations, while defense lawyers may argue that legitimate services, coding disagreements, coverage ambiguities, documentation errors, delegated work, or good-faith clinical decisions account for some or all disputed reimbursements.
How Medicare Part B Produced the Payments
Medicare Part B generally covers qualifying medical items and professional services furnished by physicians, nurse practitioners, group practices, and other enrolled providers, but reimbursement depends upon accurate claims, documented medical necessity, truthful service descriptions, and compliance with governing program rules.
The indictment says Tesar enrolled as an individual Medicare practitioner before reassigning her benefits to Tesar Primecare LLC, a Sarasota business registered with Medicare as a single-specialty or multispecialty clinic or group practice capable of submitting claims.
Each claim was expected to identify the beneficiary, describe the item or service, supply billing codes, specify the treatment date, and name the ordering, referring, or rendering provider, creating a structured record that investigators could later compare against underlying clinical evidence.
In Florida, First Coast Service Options served as the Medicare Administrative Contractor responsible for adjudicating relevant Part B claims, applying coverage rules, processing submissions, and issuing payments on behalf of the Centers for Medicare and Medicaid Services.
That intermediary role helps explain how an alleged false claim becomes a real federal payment, because a contractor evaluates information supplied through the billing process without necessarily observing the wound, meeting the patient, or watching the reported allograft application.
Prosecutors contend that the submissions appeared eligible because patient records were made to support medical necessity and service delivery, while the indictment alleges that some of those records contained false treatment histories, backdated documentation, or inaccurate descriptions of patient conditions.
The Products Behind the High-Dollar Claims
The wound products included certain bioengineered skin substitutes and amniotic membrane allografts made from human placental tissue, which may be placed over qualifying open wounds to assist closure or encourage skin growth when an appropriate clinical assessment supports their use.
These products can serve legitimate and important medical purposes, particularly for difficult diabetic foot ulcers or venous leg ulcers that have not improved through conservative care, so the prosecution does not mean every allograft treatment or high reimbursement is improper.
The government’s theory instead focuses on whether the products billed in this case were medically reasonable, medically necessary, accurately documented, delivered as represented, eligible under applicable coverage requirements, and unconnected to prohibited financial inducements or patient-referral payments.
According to prosecutors, Tesar sometimes selected allografts solely to maximize profit, used products without establishing prior conservative treatment, continued applications after treatments were not working, and applied grafts to infected wounds or wounds unlikely to heal.
The indictment additionally alleges that Medicare received claims for applications that never occurred, a contention that turns part of the dispute from a debate over clinical judgment into an accusation that reimbursement was requested for services patients did not receive.
Five Claims Show How Billings Became Payments
Counts one through five identify five representative transactions involving beneficiaries described only by initials, allowing prosecutors to place specific service dates, submission dates, billed charges, and Medicare payments inside the broader allegation involving more than $118 million.
For the first beneficiary, prosecutors identify an October 2024 service followed by a November submission seeking approximately $288,350, after which Medicare paid approximately $199,769 on a claim the government says falsely represented necessity, eligibility, performance, and kickback compliance.
The second count concerns a March 2025 service that was submitted in July for approximately $1.11 million, resulting in an alleged Medicare payment of approximately $854,311 and representing the largest individual payment among the five charged claim examples.
The third count identifies a May 2025 service billed in July for approximately $1.06 million, with Medicare paying approximately $727,168, while the fourth describes approximately $871,200 billed and approximately $599,583 paid for another March service submitted during August.
The fifth count concerns an August 2025 service submitted only two days later, according to the indictment, with approximately $630,475 billed to Medicare and approximately $443,043 paid through the federal program’s claims-processing system.
Together, those five counts describe approximately $3.96 million billed and approximately $2.82 million paid, offering jurors a manageable group of patient-level episodes through which the government may seek to prove a much larger alleged pattern.
The defense can examine each episode independently, challenging the wound assessment, treatment records, product quantity, coding, claim preparation, reimbursement eligibility, service performance, and relationship between any disputed payment and the alleged referral structure described elsewhere in the indictment.
Referral Payments Allegedly Fed the Billing Pipeline
Prosecutors allege that Presha and Evans appeared to work as sales representatives for an unnamed Pennsylvania allograft company, although their true role was allegedly finding Medicare beneficiaries with wounds and referring those patients to Tesar in exchange for compensation.
That company allegedly entered sham sales agreements with purported representatives, received payments from Primecare for allograft products, and later transmitted money linked to identified products, patients, and representatives, creating the disputed financial pathway underlying the kickback counts.
The indictment describes a September 2024 communication in which more than $4.06 million in invoices was paired with a twenty-percent calculation totaling $813,925, evidence prosecutors may use to connect payment expectations directly with product-related revenue.
Later communications allegedly compared a product costing $2,000 per square centimeter with another costing $1,591, discussed the higher twenty-percent return associated with the more expensive option, and described an intention to switch patients toward that product.
On August 15, 2025, prosecutors say the Pennsylvania company transferred approximately $397,570 into an account connected with Presha and approximately $10,998 into an account connected with Evans, transactions charged from both the payment and receipt sides.
The defendants may contest whether those transfers represented illegal remuneration, legitimate compensation, misunderstood commercial activity, or money lacking the required connection to federally reimbursed referrals, because the government must prove knowing and willful participation rather than suspicious appearance alone.
Coverage Rules Created the Alleged Gatekeeper
Florida wound-care coverage guidance required continuing treatment to be supported by records showing improvement, accepted treatment standards, evaluation of conditions affecting healing, and a duration reasonably connected to the patient’s expected potential for restoration.
For covered diabetic foot ulcers and venous leg ulcers, the indictment describes a requirement for at least four weeks of completed and documented conservative care, including measures such as debridement, pressure relief, infection control, and management of wound drainage.
The governing policy also expected a provider to use one specific skin-substitute product during a defined twelve-week treatment course, discouraged switching products, and treated repeat applications as unreasonable when an earlier application had already failed.
Active infections, uncontrolled underlying conditions, inadequate conservative treatment, and little realistic potential for healing could therefore undermine coverage, making accurate clinical documentation the essential gatekeeper between a medically defensible application and an ineligible federal claim.
Prosecutors allege that this gatekeeper was bypassed through records falsely describing earlier care, treatments that never happened, older documentation dates, and patient conditions framed to justify graft applications, allegations the defense will be entitled to test thoroughly.
Patients Were More Than Billing Identifiers
The indictment portrays Medicare beneficiaries as targets within the alleged operation, claiming that some patients were encouraged to begin or continue costly treatments through misrepresented prices, improperly waived copayments, free medical supplies, jewelry, and a leather recliner.
Beneficiary inducements matter because patients often rely heavily upon licensed professionals when deciding whether repeated wound treatments are necessary, especially when age, disability, chronic disease, reduced mobility, or terminal illness limits their ability to obtain independent guidance.
An unnecessary application can impose pain, infection exposure, repeated visits, disrupted hospice priorities, and emotional strain even when Medicare absorbs most of the financial charge, meaning alleged patient harm cannot be measured solely by the government’s reimbursement total.
At the same time, beneficiaries whose initials appear in the case should not be publicly blamed or identified, because prosecutors describe them as people whose treatment and insurance status were allegedly exploited rather than as architects of the commercial relationships.
Responsible reporting must therefore explain the payment trail without publishing unnecessary medical details, speculating about individual diagnoses, or treating patients as props within a financial narrative that already contains enough verified information to serve the public interest.
An Audit Allegedly Changed the Corporate Picture
The indictment says a Medicare audit preceded Tesar’s removal of her name as Primecare’s owner from Florida corporate records, although prosecutors claim she continued exercising ownership and managerial control while disputed claims remained under federal scrutiny.
Prosecutors characterize that change as an effort to evade further Medicare attention, while defense counsel may offer lawful business, administrative, ownership, or timing explanations and challenge whether the filing demonstrates consciousness of wrongdoing rather than an unrelated corporate decision.
Audits can become pivotal evidence because they establish when a provider learned that regulators were questioning claims, what documents were available at that moment, whether billing practices changed afterward, and who retained authority over operations and money.
Investigators can then compare corporate filings with bank signatures, payroll records, vendor communications, electronic access, patient assignments, claim submissions, and internal instructions to determine whether formal ownership matched the person actually directing the business.
The Government Followed the Money into Accounts
Federal authorities say they seized approximately $11.8 million in assets connected with the case, including money held in bank and investment accounts, while the indictment seeks forfeiture of alleged criminal proceeds and substitute assets under specified circumstances.
The forfeiture section attributes approximately $61.63 million in alleged proceeds to Tesar, approximately $3.19 million to Presha, and approximately $263,223 to Evans, although those figures remain prosecutorial allegations rather than final judicial determinations of criminal ownership.
The indictment lists four seizures connected with Tesar, including approximately $1.01 million from a bank account, $8 million from an investment account, approximately $867,862 from another bank account, and approximately $1.91 million from the investment account.
Those listed seizures closely explain the government’s announced $11.8 million recovery, but seizure does not automatically establish forfeiture, because defendants and qualifying third parties can contest traceability, ownership, statutory authority, and the government’s characterization of particular funds.
If directly traceable proceeds cannot be located, have been transferred, moved beyond the court’s jurisdiction, diminished substantially, or commingled beyond practical division, prosecutors seek authority to pursue substitute property under federal forfeiture provisions cited in the indictment.
Alleged Spending Added a Vivid Narrative
Prosecutors further allege that fraud proceeds supported extravagant personal spending, including more than $215,000 for Tampa Bay Buccaneers tickets and a luxury suite at Raymond James Stadium, together with more than $400,000 spent on fine art.
Those purchases give the government a memorable illustration of where allegedly diverted program money went, yet luxury consumption alone cannot prove health-care fraud, kickback intent, medical falsity, or the criminal origin of any particular dollar.
At trial, financial evidence becomes meaningful when prosecutors connect claim payments to business accounts, product purchases, transfers, personal expenditures, and alleged concealment, thereby building a chronology that links Medicare reimbursement with the conduct charged in specific counts.
Defense lawyers can challenge that chronology by identifying legitimate income, lawful transfers, jointly owned assets, unrelated purchases, accounting errors, or breaks in traceability, while also arguing that spending legally earned money is not evidence of criminal intent.
The Tesar Case Joined a National Crackdown
The charges were announced during the Justice Department’s 2026 National Health Care Fraud Takedown, a coordinated operation involving hundreds of defendants and billions of dollars in alleged claims across numerous federal districts, health-care specialties, and payment systems.
Contemporaneous reporting from WWSB described the Sarasota prosecution as an alleged $118 million wound-care scheme and reported the government’s central assertions concerning unnecessary grafts, referral kickbacks, approximately $61 million in payments, and substantial asset seizures.
National enforcement increasingly combines claims analytics with traditional investigative work, enabling authorities to identify abrupt billing growth, unusually expensive product choices, repeated services, shared beneficiaries, connected referral sources, and financial patterns spanning multiple companies or jurisdictions.
Data may reveal where investigators should look, but an algorithm cannot independently prove criminal knowledge, making witness testimony, authenticated communications, medical expertise, patient files, invoices, inventory records, bank transfers, and ownership evidence essential to any eventual conviction.
The Tesar indictment reflects that combined approach by pairing massive aggregate figures with five charged claims, quoted communications, named transfers, specified business accounts, coverage requirements, alleged record falsification, an audit response, and a detailed forfeiture demand.
Compliance Lessons for Wound-Care Providers
Legitimate providers should treat explosive reimbursement growth as a reason for immediate independent review, particularly when revenue depends upon expensive products, outside patient recruiters, percentage-based compensation, repeated applications, or documentation created after treatment decisions have already been made.
Clinical controls should verify wound measurements, infection status, conservative treatment, healing progress, product selection, application frequency, and restoration potential before billing, with decision-makers insulated from vendor incentives and compensation tied to product price or Medicare reimbursement.
Financial controls should reconcile each allograft purchase with inventory, a named beneficiary, an application date, a clinical record, a submitted claim, a received payment, and any unused material, allowing discrepancies to surface before they become systemic liabilities.
Organizations should also review copayment waivers and patient assistance carefully, because well-intended support can become an unlawful inducement when offered selectively to attract beneficiaries, prolong services, or remove resistance to treatment carrying unusually high federal reimbursement.
Written contracts do not make a referral relationship lawful when compensation depends upon federally insured business, so compliance teams must test whether marketers perform genuine services, receive fair-market payment, and remain independent from clinical and product-selection decisions.
Public Allegations Create a Second Crisis
Criminal charges immediately create a parallel reputational emergency for defendants, clinics, employees, patients, and commercial partners, because search results can spread indictment allegations worldwide long before discovery, motions, negotiations, dismissals, pleas, or trials clarify the evidentiary record.
Ethical crisis public-relations management should coordinate with legal counsel, distinguish accusations from established facts, protect patient confidentiality, correct demonstrable errors, and avoid statements that could intimidate witnesses, prejudice proceedings, or contradict positions presented in court.
Longer-term reputation rebuilding must likewise rely on truthful, verifiable developments rather than manufactured narratives, because any acquittal, dismissal, plea, conviction, restitution order, cooperation agreement, or professional disciplinary outcome may materially change what responsible public coverage should say.
Search optimization cannot erase a valid indictment or substitute publicity for adjudication, but accurate updates can prevent an unresolved accusation from becoming the only permanent account available to patients, employers, business partners, regulators, and the broader public.
What Prosecutors Must Prove Next
Tesar faces five substantive health-care fraud counts, one conspiracy count, and two counts alleging payment of health-care kickbacks, while Presha and Evans face the conspiracy charge and separate counts accusing them of receiving disputed kickback payments.
For the fraud counts, prosecutors must prove the required knowing and willful execution of a scheme involving materially false representations, while the kickback counts require evidence that prohibited remuneration was intentionally offered, paid, solicited, or received for covered referrals.
The defense may challenge electronic messages, searches, seizures, financial tracing, expert conclusions, claim coding, record authorship, treatment necessity, product quantities, witness credibility, and whether separate commercial activities truly formed the unified criminal agreement alleged by prosecutors.
Pretrial proceedings may determine which evidence jurors can consider, while expert testimony will likely address Medicare coverage, wound progression, allograft use, documentation standards, claim adjudication, and the difference between poor medical practice, civil noncompliance, administrative error, and criminal fraud.
The forfeiture dispute will unfold alongside the criminal case, requiring courts to assess whether listed property represents gross proceeds traceable to charged offenses and whether any outside owner possesses a legitimate interest protected under federal law.
A $61 Million Allegation, not a Final Judgment
The central allegation is stark: prosecutors say more than $118 million was billed during approximately eighteen months and Medicare paid over $61 million for wound-care claims allegedly involving unnecessary products, ineligible services, unperformed applications, falsified records, and prohibited referrals.
Yet the scale of that allegation makes precision more important, not less, because billed charges, allowed amounts, paid reimbursements, seized assets, alleged proceeds, representative claims, and charged transactions describe different measurements that should never be carelessly merged.
For Medicare and taxpayers, the case raises urgent questions about how quickly high-cost wound claims can accelerate before audits, analytics, payment safeguards, or investigators halt suspected abuse and recover funds that may remain traceable.
For health-care providers, the indictment demonstrates how clinical judgment, documentation, referral compensation, patient inducements, product economics, corporate ownership, and claims processing can become interconnected evidence when investigators believe a reimbursement model has displaced patient-centered care.
For Tesar, Presha, and Evans, however, the decisive process remains ahead, and only admissible evidence tested in court can determine whether Medicare’s disputed $61 million payment resulted from the criminal conduct prosecutors have alleged.
Until that adjudication occurs, responsible coverage should preserve both sides of the essential legal reality: the government has presented a detailed and financially consequential accusation, while every named defendant remains presumed innocent unless proven guilty beyond a reasonable doubt.